Prospective assessment of tizanidine for spasticity due to acquired brain injury Jay M. Meythaler, MD, JD, Sharon Guin-Renfroe, RN, MSN, Alice Johnson, BSN, CCRC, Robert M. Brunner, MD Archives of Physical Medicine and Rehabilitation Volume 82, Issue 9, Pages 1155-1163 (September 2001) DOI: 10.1053/apmr.2001.25141 Copyright © 2001 American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation Terms and Conditions
Fig. 1 The average tone (Ashworth score) in the LEs that had abnormal tone on admission to the study. Data are reported for patients, during the tizanidine (blue line) and placebo (red line) arms, at the start of treatment and after 2, 4, and 6 weeks of treatment with 1 SD bars. Archives of Physical Medicine and Rehabilitation 2001 82, 1155-1163DOI: (10.1053/apmr.2001.25141) Copyright © 2001 American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation Terms and Conditions
Fig. 2 The average tone (Ashworth score) in the UEs that had abnormal tone on admission to the study. Data are reported for patients, during the tizanidine (blue line) and placebo (red line) arms, at the start of treatment and after 2, 4, and 6 weeks of treatment with 1 SD bars. Archives of Physical Medicine and Rehabilitation 2001 82, 1155-1163DOI: (10.1053/apmr.2001.25141) Copyright © 2001 American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation Terms and Conditions
Fig. 3 The average daily dose of 4-mg tizanidine tablets (blue line) and placebo drug (red line) for patients at the start of treatment and after 2, 4, and 6 weeks of treatment with 1 SD bars. Archives of Physical Medicine and Rehabilitation 2001 82, 1155-1163DOI: (10.1053/apmr.2001.25141) Copyright © 2001 American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation Terms and Conditions
Fig. 4 Motor strength as graded on the 1 to 5 scale for those extremities that had abnormal tone at the start of the study (Start) and after 6 weeks of treatment on the active drug (Active 6 weeks). Archives of Physical Medicine and Rehabilitation 2001 82, 1155-1163DOI: (10.1053/apmr.2001.25141) Copyright © 2001 American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation Terms and Conditions